Abbott Laboratories (ABT) Stock Forecast & Price Target

$114.87

-3.26 (-2.76%)

(As of 09/18/2024 ET)

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, and 7 have given a buy rating for ABT.

Consensus Price Target

$121.80
6.03% Upside

High Forecast	$143.00
Average Forecast	$121.80
Low Forecast	$107.00

According to the 9 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $121.80. The highest price target for ABT is $143.00, while the lowest price target for ABT is $107.00. The average price target represents a forecasted upside of 6.03% from the current price of $114.87.

Type	Current Forecast 9/19/23 to 9/18/24	1 Month Ago 8/20/23 to 8/19/24	3 Months Ago 6/21/23 to 6/20/24	1 Year Ago 9/19/22 to 9/19/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$121.80	$121.00	$120.64	$120.82
Forecasted Upside	6.03% Upside	18.58% Upside	15.79% Upside	12.68% Upside

Massive shakeup in defense contracting (Ad)

There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.

You need to check out the full story right here.

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	6.03% Upside	1,014.34% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/22/2024	Citigroup 3 of 5 stars	Boost Target	Buy ➝ Buy	$119.00 ➝ $127.00	+13.95%
7/30/2024	Edward Jones 3 of 5 stars	Downgrade	Buy ➝ Hold
7/29/2024	Barclays 3 of 5 stars	Boost Target	Overweight ➝ Overweight	$140.00 ➝ $143.00	+37.90%
7/2/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$125.00 ➝ $120.00	+16.34%
6/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$125.00 ➝ $125.00	+21.60%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$121.00	+20.11%
Here comes the May Shockwave (Ad) Now that the Fed has spoken, it’s sure to create a May Shockwave! Now's your best chance to trade this historic event using the method that has seen Doubles, Even Triples within just a few days! You see, while most folks will be paying $500… $1,000… or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options in a volatile market. You see, by entering on certain predetermined dates, we have been able to watch as these $0.25 Cent Trades doubled, even tripled in what feels like no time. Click here to see the details so you don’t miss the next $0.25 Cent Trade!
4/24/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$124.00	+15.27%
12/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$116.00 ➝ $121.00	+13.70%
10/19/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$130.00 ➝ $118.00	+25.35%
10/19/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$112.00 ➝ $107.00	+13.23%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$120.00 ➝ $112.00	+17.41%
7/21/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$110.00 ➝ $115.00	+2.85%
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
4/20/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$132.00 ➝ $133.00	+19.44%
4/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight	$118.00 ➝ $122.00	+9.56%
4/17/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$125.00 ➝ $130.00	+25.05%
3/31/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform	$90.00 ➝ $102.00	+2.95%
3/30/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$125.00 ➝ $115.00	+16.61%
1/26/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$110.00 ➝ $125.00	+12.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:42 PM ET.

ABT Forecast - Frequently Asked Questions

What is Abbott Laboratories' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $121.80, with a high forecast of $143.00 and a low forecast of $107.00.
Should I buy or sell Abbott Laboratories stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.
Does Abbott Laboratories's stock price have much upside?: According to analysts, Abbott Laboratories's stock has a predicted upside of 18.50% based on their 12-month stock forecasts.
Has Abbott Laboratories been downgraded by Wall Street analysts recently?: Over the previous 90 days, Abbott Laboratories's stock had 1 downgrade by analysts.
What analysts cover Abbott Laboratories?: Abbott Laboratories has been rated by research analysts at Barclays, Citigroup, Edward Jones, and Evercore ISI in the past 90 days.
Do Wall Street analysts like Abbott Laboratories more than its competitors?: Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.78 while the average consensus rating score for "medical" companies is 2.77. Learn more on how ABT compares to other companies.